Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 May;4(3):264–269. doi: 10.1128/cdli.4.3.264-269.1997

Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.

G A Losonsky 1, Y Lim 1, P Motamedi 1, L E Comstock 1, J A Johnson 1, J G Morris Jr 1, C O Tacket 1, J B Kaper 1, M M Levine 1
PMCID: PMC170516  PMID: 9144361

Abstract

The emergence of a new agent of cholera, Vibrio cholerae O139, has prompted a reevaluation of the vibriocidal antibody assay. This assay, primarily directed to lipopolysaccharide, is an important correlate of O1 immunity. V. cholerae O139 strains are encapsulated, rendering them relatively resistant to killing by serum. Recent reports suggest that there is strain-to-strain variability in the sensitivity of the vibriocidal assay to fully encapsulated O139 strains. We have assessed a modified vibriocidal assay for fully encapsulated O139 strain AI-1837 and its unencapsulated mutant 2L in sera from 53 volunteers given wild-type AI-1837 or its attenuated derivative CVD 112 and from 48 controls challenged with V. cholerae O1 or strains of the family Enterobacteriaceae. Vibriocidal responses to the AI-1837 and 2L strains were seen in 67 and 89% of volunteers, respectively, following a single exposure to the wild-type strain. However, >50% of all controls had low-level vibriocidal responses to both strains. These nonspecific responses were transient and of the immunoglobulin G isotype. No binding activity against purified O139 lipopolysaccharide (LPS) by immunoblotting was seen in control sera. In contrast, vibriocidal assay and strain 2L LPS responses by immunoblotting were detectable in 91% of tested volunteers following a single exposure to O139. The presence of vibriocidal antibody to AI-1837 or 2L was not associated with protection in rechallenge studies with O139 strain AI-1837. The vibriocidal assay with unencapsulated strain 2L may be used to detect exposure to O139 strain AI-1837 in controlled research trials. However, its lack of specificity does not make it useful for determining exposure to V. cholerae O139 in the field.

Full Text

The Full Text of this article is available as a PDF (275.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert M. J., Ansaruzzaman M., Shimada T., Rahman A., Bhuiyan N. A., Nahar S., Qadri F., Islam M. S. Characterization of Aeromonas trota strains that cross-react with Vibrio cholerae O139 Bengal. J Clin Microbiol. 1995 Dec;33(12):3119–3123. doi: 10.1128/jcm.33.12.3119-3123.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Albert M. J. Vibrio cholerae O139 Bengal. J Clin Microbiol. 1994 Oct;32(10):2345–2349. doi: 10.1128/jcm.32.10.2345-2349.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clements M. L., Levine M. M., Young C. R., Black R. E., Lim Y. L., Robins-Browne R. M., Craig J. P. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982 Apr;145(4):465–473. doi: 10.1093/infdis/145.4.465. [DOI] [PubMed] [Google Scholar]
  4. Comstock L. E., Maneval D., Jr, Panigrahi P., Joseph A., Levine M. M., Kaper J. B., Morris J. G., Jr, Johnson J. A. The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun. 1995 Jan;63(1):317–323. doi: 10.1128/iai.63.1.317-323.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coster T. S., Killeen K. P., Waldor M. K., Beattie D. T., Spriggs D. R., Kenner J. R., Trofa A., Sadoff J. C., Mekalanos J. J., Taylor D. N. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet. 1995 Apr 15;345(8955):949–952. doi: 10.1016/s0140-6736(95)90698-3. [DOI] [PubMed] [Google Scholar]
  6. Donnenberg M. S., Tacket C. O., James S. P., Losonsky G., Nataro J. P., Wasserman S. S., Kaper J. B., Levine M. M. Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest. 1993 Sep;92(3):1412–1417. doi: 10.1172/JCI116717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Glass R. I., Svennerholm A. M., Khan M. R., Huda S., Huq M. I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985 Feb;151(2):236–242. doi: 10.1093/infdis/151.2.236. [DOI] [PubMed] [Google Scholar]
  8. Hone D. M., Tacket C. O., Harris A. M., Kay B., Losonsky G., Levine M. M. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest. 1992 Aug;90(2):412–420. doi: 10.1172/JCI115876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnson J. A., Salles C. A., Panigrahi P., Albert M. J., Wright A. C., Johnson R. J., Morris J. G., Jr Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences. Infect Immun. 1994 May;62(5):2108–2110. doi: 10.1128/iai.62.5.2108-2110.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaper J. B., Morris J. G., Jr, Levine M. M. Cholera. Clin Microbiol Rev. 1995 Jan;8(1):48–86. doi: 10.1128/cmr.8.1.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kotloff K. L., Nataro J. P., Losonsky G. A., Wasserman S. S., Hale T. L., Taylor D. N., Sadoff J. C., Levine M. M. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 1995 Nov;13(16):1488–1494. doi: 10.1016/0264-410x(95)00102-7. [DOI] [PubMed] [Google Scholar]
  12. Losonsky G. A., Johnson J. P., Winkelstein J. A., Yolken R. H. Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest. 1985 Dec;76(6):2362–2367. doi: 10.1172/JCI112248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Morris J. G., Jr, Losonsky G. E., Johnson J. A., Tacket C. O., Nataro J. P., Panigrahi P., Levin M. M. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J Infect Dis. 1995 Apr;171(4):903–908. doi: 10.1093/infdis/171.4.903. [DOI] [PubMed] [Google Scholar]
  14. Mosley W. H., Ahmad S., Benenson A. S., Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ. 1968;38(5):777–785. [PMC free article] [PubMed] [Google Scholar]
  15. Mosley W. H., Benenson A. S., Barui R. A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ. 1968;38(3):327–334. [PMC free article] [PubMed] [Google Scholar]
  16. Nataro J. P., Deng Y., Cookson S., Cravioto A., Savarino S. J., Guers L. D., Levine M. M., Tacket C. O. Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis. 1995 Feb;171(2):465–468. doi: 10.1093/infdis/171.2.465. [DOI] [PubMed] [Google Scholar]
  17. Noriega F. R., Losonsky G., Wang J. Y., Formal S. B., Levine M. M. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect Immun. 1996 Jan;64(1):23–27. doi: 10.1128/iai.64.1.23-27.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Qadri F., Mohi G., Hossain J., Azim T., Khan A. M., Salam M. A., Sack R. B., Albert M. J., Svennerholm A. M. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol. 1995 Nov;2(6):685–688. doi: 10.1128/cdli.2.6.685-688.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. ROBBINS J. B., KENNY K., SUTER E. THE ISOLATION AND BIOLOGICAL ACTIVITIES OF RABBIT GAMMA M- AND GAMMA G-ANTI-SALMONELLA TYPHIMURIUM ANTIBODIES. J Exp Med. 1965 Aug 1;122:385–402. doi: 10.1084/jem.122.2.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sengupta D. K., Boesman-Finkelstein M., Finkelstein R. A. Antibody against the capsule of Vibrio cholerae O139 protects against experimental challenge. Infect Immun. 1996 Jan;64(1):343–345. doi: 10.1128/iai.64.1.343-345.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tacket C. O., Losonsky G., Nataro J. P., Comstock L., Michalski J., Edelman R., Kaper J. B., Levine M. M. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis. 1995 Sep;172(3):883–886. doi: 10.1093/infdis/172.3.883. [DOI] [PubMed] [Google Scholar]
  22. Tacket C. O., Losonsky G., Nataro J. P., Wasserman S. S., Cryz S. J., Edelman R., Levine M. M. Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O. Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):75–77. doi: 10.1016/0035-9203(95)90667-3. [DOI] [PubMed] [Google Scholar]
  23. Waldor M. K., Colwell R., Mekalanos J. J. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11388–11392. doi: 10.1073/pnas.91.24.11388. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES